| ￥1600 | |
| Z06290-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 42.9 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 48-51 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution inPBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
NTS1 hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Neurotensin (NT) is an endogenous 13 amino acid neuropeptide with profound opioid-independent analgesic effects. This role of NT is thought to be mediated by both neurotensin receptor subtype 1 (NTS1) and neurotensin receptor subtype 2 (NTS2). NT and its receptors are widely distributed in the pain circuits in central nervous system. |
| Synonyms | NT; NTR; NTR1; NTRH; NTRR; NTS1; NTSR1; NMN-125; NN; NT/N; Neurotensin/neuromedin N; Neurotensin |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
